skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8129

Treatment and prevention of mania in bipolar I disorder: focus on aripiprazole

Review

(3050) Views  (830) Full article downloads

Author: David J Muzina

Published Date May 2009 Volume 2009:5 Pages 279 - 288
DOI: http://dx.doi.org/10.2147/NDT.S3763

David J Muzina

Center for Mood Disorders Treatment and Research, Cleveland Clinic Neurological Institute, Cleveland, Ohio, USA

Abstract: Aripiprazole is a second-generation antipsychotic with a unique pharmacologic receptor profile that has efficacy in the treatment and prevention of mania in bipolar I disorder. This article reviews the evidence supporting treatment of adults with bipolar I disorder using aripiprazole as monotherapy or adjunctively during acute mania and its utility as an intramuscular agent for agitation in manic patients. Results from one of the longest bipolar maintenance trials which support aripiprazole as a prophylactic mood stabilizer, specifically against manic relapses, will be discussed as well as a post-hoc analysis that suggests efficacy for rapid cycling bipolar disorder. Safety and tolerability issues, patient-focused perspectives and aripiprazole’s place in therapy for bipolar mania will be covered.

Keywords: bipolar disorder, mania, prevention, aripiprazole, rapid cycling






 

Other articles by Dr David Muzina

A large pharmacy claims-based descriptive analysis of patients with migraine and associated pharmacologic treatment patterns